CluePoints to Launch New Web Application for Risk-Based Monitoring at DIA 2014 - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
CluePoints to Launch New Web Application for Risk-Based Monitoring at DIA 2014

Source: Applied Clinical Trials

CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has announced a web-based version of its intelligent risk-based monitoring platform that enables sponsors to determine the quality and integrity of their clinical trial data. The web-based CSM software as a service (SaaS) offering will enable customers to control the upload of clinical data for assessment, visualize the findings and interact with analyses to make the understanding of results, comprehension of signals and identification of issues as intuitive as possible. CluePoints will showcase this new platform, alongside the company's portfolio of CSM solutions, on booth #733 during the DIA 2014 Annual Meeting being held from June 15-19, in San Diego, CA.

CluePoints' solutions are driven by the company's intelligent, patent-pending SMART™ engine that provides customers with the ability to check data quality across all clinical subjects, sites, regions and countries involved in a trial, achieving data consistency, while documenting where and why any anomalies have occurred. Aligned with current FDA and EMA recommendations, the approach ensures that users are able to identify signals in study datasets and can make timely decisions about which sites to target for monitoring activities, resulting in reduced regulatory submission risk and costs.

This first version of the web portal aims to put the sponsor in control so that they can run the analysis, set-up the SMART engine, construct and manage data within the system, select appropriate statistical tests and perform the complete CSM process independently and objectively. Continuous improvements will be brought to the software to meet clients’ needs: a second release will soon support closer to real-time assessments of data and generate a customized report whenever required.

"The launch of CluePoints' web-portal marks another exciting industry first for CluePoints as it enables sponsors and contract research organizations (CROs) to drive their own analyses using actual clinical data, rather than just subjective operational metrics, for the first time", comments Franҫois Torche, CEO of CluePoints. He continues: "We are continually working to enhance the usability of our solutions to meet current industry needs and through discussions with our clients have found that many companies would like to take full control of their risk-based monitoring analyses using clinical databases. The new SaaS solution enables them to do this."

To offer sponsors and CROs detailed insight into the practical implementation of CSM solutions, a new webinar from CluePoints in collaboration with Sanofi Aventis is now available online, entitled 'Risk-Based Monitoring – What we’ve learnt in a year, a Large Pharma Perspective from Sanofi'. The session demonstrates how CSM techniques have been harnessed to improve data quality and oversight, while showcasing the impact that Sanofi has had on enhancing this technology-driven approach. To download the webinar, visit http://register.xtalks.com/Surveys/Questions/SurveyMain.aspx?r=47501705-e435-48ba-a5fe-909e9163c011&ma=0

For further information on CluePoints' solutions, please visit www.CluePoints.com or booth #733 at the DIA 2014 Annual Meeting.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here